First Manhattan’s Beam Therapeutics BEAM Stock Holding History

First Manhattan’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-400	Closed	-$9.62K	–	1448
2023 Q3	$9.62K	Hold	400	–	–	﹤0.01%	1138
2023 Q2	$12.8K	Hold	400	–	–	﹤0.01%	1098
2023 Q1	$12.2K	Hold	400	–	–	﹤0.01%	1171
2022 Q4	$15.6K	Hold	400	–	–	﹤0.01%	1163
2022 Q3	$19K	Hold	400	–	–	﹤0.01%	1093
2022 Q2	$15K	Hold	400	–	–	﹤0.01%	1160
2022 Q1	$22K	Hold	400	–	–	﹤0.01%	1135
2021 Q4	$31K	Hold	400	–	–	﹤0.01%	1089
2021 Q3	$34K	Hold	400	–	–	﹤0.01%	1059
2021 Q2	$51K	Hold	400	–	–	﹤0.01%	982
2021 Q1	$32K	Hold	400	–	–	﹤0.01%	1050
2020 Q4	$32K	Hold	400	–	–	﹤0.01%	976
2020 Q3	$9K	Buy	+400	New	+$9.92K	﹤0.01%	1131

Other funds holding BEAM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

First Manhattan's BEAM Position: Q4 2023 in Review

First Manhattan sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 400 shares — an estimated $9.62K sold.

First Manhattan first reported a position in BEAM in Q3 2020 and held it in 13 quarters. The position peaked at $51K in Q2 2021. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

First Manhattan reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 400 Beam Therapeutics shares in Q4 2023, an estimated $9.62K.
First Manhattan first reported a position in Beam Therapeutics in Q3 2020 and held it in 13 quarters.
First Manhattan's Beam Therapeutics position peaked at $51K in Q2 2021.
185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.